CFO transition
Rani Therapeutics Holdings, Inc. CFO transition: Nicholas M. Maestas to succeed Svai Sanford
Rani Therapeutics Holdings, Inc. reported in a Form 8-K filed June 30, 2026 that Nicholas M. Maestas will succeed Svai Sanford as Chief Financial Officer (principal financial officer and principal accounting officer), effective June 29, 2026.
In the filing's words
On June 29, 2026, Rani Therapeutics Holdings, Inc. (the “Company”) announced the appointment of Nicholas M. Maestas as the Company’s Chief Financial Officer (principal financial officer and principal accounting officer) effective as of June 29, 2026.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Rani Therapeutics Holdings, Inc. (RANI) |
|---|---|
| Event | Transition |
| Incoming | Nicholas M. Maestas |
| Outgoing | Svai Sanford |
| Title in the filing | Chief Financial Officer (principal financial officer and principal accounting officer) |
| Effective | June 29, 2026 |
| 8-K filed | June 30, 2026 |
| Internal promotion | No |
| Prior role (per filing) | Chief Financial Officer and Head of Corporate Strategy, Tempest Therapeutics, Inc. |
| SEC CIK | 0001856725 |
Rani Therapeutics Holdings, Inc. reported this change in a Form 8-K, Item 5.02, filed June 30, 2026. The filing's own words are quoted above.
Other records naming Svai Sanford
1The outgoing officer on this record, matched by name. Career line.
2026-03-26 · 10-K signature
Svai Sanford signed Rani Therapeutics Holdings, Inc.'s annual report as Chief Financial Officer (Principal Financial and Accounting Officer)
Same industry, June 2026
8Other moves filed that month at companies the roster files under SIC “Pharmaceutical Preparations”.
4 months ago· 2026-06-30InterimIMNN
Imunon, Inc. names Josh Blacher interim CFO
4 months ago· 2026-06-29InterimCVKD
Cadrenal Therapeutics, Inc. names John P. Sharp interim CFO
5 months ago· 2026-06-18InterimMPLT
MapLight Therapeutics, Inc. names Jonathan Gillis interim CFO
5 months ago· 2026-06-18TransitionPTPI
Petros Pharmaceuticals, Inc. CFO transition: Robert Weinstein to succeed Mitchell Arnold
5 months ago· 2026-06-15AppointmentSNSE
Sensei Biotherapeutics, Inc. appoints Brian Stephenson as CFO
5 months ago· 2026-06-12AppointmentOCUL
Ocular Therapeutix, Inc. appoints Jason Robins as CFO
5 months ago· 2026-06-04AppointmentBYSI
BeyondSpring Inc. appoints Na Li as CFO
5 months ago· 2026-06-03InterimCVKD
Cadrenal Therapeutics, Inc. names Quang X. Pham interim CFO
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Nicholas M. Maestas? Send a correction with the primary source.